Cite
HARVARD Citation
Ohman, E. et al. (2017). Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 389 (10081), pp. 1799-1808. [Online].